Christopher Johnson

OverviewAI-generated summary

Christopher Johnson's research focuses on the pharmacological management of chronic diseases, particularly inflammatory bowel disease (IBD) and type-2 diabetes with cardiovascular disease. He investigates the efficacy and safety of therapeutic agents, including guselkumab for Crohn's disease and the utilization and costs associated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in managing type-2 diabetes and cardiovascular disease.

His work also extends to understanding factors influencing patient outcomes and healthcare utilization. This includes examining the role of medical and social determinants of health in predicting adverse outcomes for patients with IBD and the impact of outpatient follow-up on hospital readmission rates in this population. Additionally, Johnson has explored the financial burden of cannabinoid hyperemesis syndrome on the healthcare industry.

Prior to his current focus, Johnson's research interests have included the genetic mechanisms of bacterial transport systems in *Enterococcus faecalis*, interactions of mobile genetic elements, and even ecological overlap studies concerning baleen whales and krill fisheries. His scholarship metrics include an h-index of 50, 155 total publications, and 14,110 total citations.

Metrics

• h-index: 50
• Publications: 155
• Citations: 14,110